Immatics (NASDAQ:IMTX) Short Interest Update

Immatics (NASDAQ:IMTX) was the recipient of a large growth in short interest in the month of October. As of October 15th, there was short interest totalling 10,020,000 shares, a growth of 5.3% from the September 30th total of 9,520,000 shares. Based on an average daily trading volume, of 487,400 shares, the short-interest ratio is presently 20.6 days.

Hedge Funds Weigh In On Immatics

Hedge funds and other institutional investors have recently modified their holdings of the company. Nan Fung Group Holdings Ltd purchased a new position in shares of Immatics in the 1st quarter valued at approximately $165,000. Affinity Asset Advisors LLC raised its position in Immatics by 75.0% during the first quarter. Affinity Asset Advisors LLC now owns 350,000 shares of the company’s stock valued at $3,678,000 after purchasing an additional 150,000 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of Immatics by 38.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,225,360 shares of the company’s stock valued at $33,899,000 after buying an additional 891,191 shares during the last quarter. Baker BROS. Advisors LP boosted its position in Immatics by 10.4% during the 1st quarter. Baker BROS. Advisors LP now owns 6,443,398 shares of the company’s stock valued at $67,720,000 after acquiring an additional 604,545 shares in the last quarter. Finally, Zimmer Partners LP lifted its holdings in shares of Immatics by 89.0% during the 1st quarter. Zimmer Partners LP now owns 397,000 shares of the company’s stock valued at $4,172,000 after purchasing an additional 187,000 shares during the last quarter. 64.41% of the stock is currently owned by hedge funds and other institutional investors.

Immatics Price Performance

Shares of IMTX opened at $9.33 on Friday. The firm has a market cap of $1.11 billion, a PE ratio of -10.48 and a beta of 0.75. The stock’s fifty day moving average price is $10.81 and its two-hundred day moving average price is $11.34. Immatics has a 1 year low of $7.80 and a 1 year high of $13.77.

Immatics (NASDAQ:IMTX) last posted its earnings results on Tuesday, August 13th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.17. Immatics had a negative return on equity of 23.34% and a negative net margin of 103.99%. The business had revenue of $20.19 million during the quarter, compared to analysts’ expectations of $12.36 million. Sell-side analysts anticipate that Immatics will post -0.93 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. Piper Sandler began coverage on Immatics in a report on Monday, October 7th. They set an “overweight” rating and a $19.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Immatics in a research note on Thursday, September 5th.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.